AE, n (%) | Daclizumab 150 mg SC |
---|---|
(N = 410) | |
Any AE leading to treatment discontinuation | 48 (12) |
Investigations | 19 (5) |
Increased ALT | 11 (3) |
Increased AST | 5 (1) |
Increased hepatic enzyme | 4 (<1) |
Skin and subcutaneous tissue disorders | 12 (3) |
Allergic dermatitis | 3 (<1) |
Gastrointestinal disorders | 4 (<1) |
Colitis | 3 (<1) |
Hepatobiliary disorders | 4 (<1) |
Infections and infestations | 4 (<1) |